Atypical antipsychotics and metabolic syndrome

Abstract

Atypical antipsychotics have become the gold standard and the first treatment option for mental illness in recent years. However, despite all the benefits provided by these drugs, a growing collection of case reports and clinical trials describing metabolic complications and body weight gain have been reported. Among atypical antipsychotic drugs, olanzapine and clozapine appear to have the highest tendency to disturb glucose metabolism compared with the other antipsychotic drugs available on the market.